Results 231 to 240 of about 9,013,142 (283)

Unique circulating miRNAome signatures captured with distinct molecular states in Lynch syndrome and sporadic colorectal cancer

Molecular Oncology, EarlyView.
Circulating microRNA profiles distinguish nonmalignant Lynch syndrome from cancer‐associated Lynch syndrome, sporadic colorectal cancer, and healthy controls. Age‐stratified analysis reveals disease‐specific regulatory states, and a six‐miRNA panel shows concordant separation in an independent colorectal tissue cohort.
Ramadhani Salum Chambuso, Md Shohel Ul Islam, Rosa M Xicola, Raj Ramesar, Xavier Llor, Sinclair Steele   +5 more
wiley   +1 more source

The VA Rural Interprofessional Faculty Development Initiative: a qualitative evaluation guided by the RE-AIM framework. [PDF]

BMC Med Educ
Keithly S, Perry P, Ho EJ, Sterling RA, Subramaniam S, Coogan S, Shirley SE, Sayre G, Helfrich C, Maynard C, Kaminetzky CP, Patel EL, Chiovaro J, Schmidt J, Stout R, Fisher A, Wong ES, Moldestad M.   +17 more
europepmc   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Process evaluation of a community-based health promotion intervention: RE- AIM framework analysis of Happy Village Plus in Sri Lanka

Wanasinghe T, Wijesinghe MSD, Alagiyawanna A, Athauda LK, Palangasinghe C, De Silva L, Wellappuli N, Verdun Z, Katulanda P, Kasturiratne A, Frost G, Sassi F, Miraldo M.   +12 more
europepmc   +1 more source

Evaluation of a behavioral intervention to support adolescents undergoing bariatric surgery using the reach, effectiveness, adoption, implementation, maintenance (RE-AIM) framework. [PDF]

Sci Rep
Allicock MA, Francis JM, Neti S, Polavarapu D, Misserian M, Mathew MS, Wheelington A, Braxton R, Cartwright BR, Qureshi FG, Atem F, Barlow SE, Messiah SE.   +12 more
europepmc   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

Implementing interpreter training for dementia assessments at national scale using the RE-AIM framework: a mixed-methods evaluation. [PDF]

BMC Geriatr
Brijnath B, Clarke N, Markusevska S, Garcia EG, Hlavac J, Low LF, Woodward-Kron R, Antoniades J, Enticott J, Gilbert AS, LoGiudice D, Lin X, Hwang K, White J, Cavuoto M.   +14 more
europepmc   +1 more source